RadNet subsidiary DeepHealth is introducing new AI-powered informatics, workflow, and integration software designed to improve operational efficiency, reduce complexities, and improve clinical confidence in imaging workflows.
DeepHealth’s core product is DeepHealth OS, a cloud-native AI-powered operating system that unifies data across clinical and operational workflows. It is being supplemented by newly launched SmartTechnology, software that seamlessly integrates AI-powered informatics with image acquisition and diagnostic interpretation.
SmartMammo and SmartSonography are new SmartTechnology modules. SmartMammo integrates AI with mammography systems to improve lesion detection accuracy and breast tissue density classification. It received U.S. Food and Drug Administration (FDA) 510(k) clearance in late November 2024 for use with GE HealthCare’s Senographe Pristina mammography systems.
SmartSonography, in combination with Siemens Healthineers’ Acuson Sequoia ultrasound device, is intended to enable real-time remote imaging support, improve diagnostic precision, and resolve ultrasound-based diagnostic workflow challenges.
DeepHealth describes its new Diagnostic Suite as a PACS-like unified diagnostic workspace with an image management layer built for AI orchestration. The still-in-development TechLive module contains a remote centralized command center to remotely access imaging devices across multiple locations without geographic constraints.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
